Skip to content
lifestyle.hoteleguide.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Moderna, Inc.
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
April 17, 2026
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
April 15, 2026
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
April 7, 2026
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
March 3, 2026
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
February 13, 2026
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
February 12, 2026
←
Previous Page
1
2
3